The long-term value of genomics companies

Journal of Chemical Technology and Biotechnology

Volumn 75, Issue 10, 2000, Pages 883-900

  Bains, William ^a  

^a Merlin Biosciences   (United Kingdom)

Author keywords

Funding; Genomics; Investment; Venture capital

Indexed keywords

COST BENEFIT ANALYSIS; DRUG PRODUCTS; MATHEMATICAL MODELS;

GENOMICS; INVESTMENT;

GENETIC ENGINEERING;

ANALGESIC AGENT; ANTIBIOTIC AGENT;

BIOMEDICAL TECHNOLOGY ASSESSMENT; CANCER; CAPITAL; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CONFERENCE PAPER; DIABETES MELLITUS; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG RESEARCH; FINANCIAL MANAGEMENT; GASTROINTESTINAL DISEASE; GENE TECHNOLOGY; GENOME; HUMAN; IMMUNOPATHOLOGY; INVESTMENT; METABOLIC DISORDER; MOLECULAR GENETICS; MYCOSIS; NEUROLOGIC DISEASE; PHARMACOGENOMICS; STOCHASTIC MODEL; VIRUS INFECTION;

EID: 0034307710     PISSN: 02682575     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-4660(200010)75:10<883::AID-JCTB298>3.0.CO;2-8     Document Type: Conference Paper

References (43)

1. Pharmaceutical biotechnology. Genetics, genomics and drug discovery
2. Drug discovery in the new millenium: The pivotal role of biotechnology
3. The genomics revolution is just beginning
4. Will genetics really revolutionize the rug discovery process?
5. Gene sequencing: The end of the beginning
6. Differentiating genomics companies
7. 1999 year end stock round-up
8. Avoiding Agrochemicals Agro. Questor column
9. Drug sector overview
10. Sykes pulls Wellcome rabbit out of the hat. Questor Column
11. Building a better biotechnology company
12. The changing dynamic: Definition and perspective
13. Industry associations: A forum for communication
14. Biopharmaceutics in discovery
15. Europe's financing iceberg
16. Gene therapy: The first decade
17. Proteomics: Translating genomics into products
18. Patient centered healthcare
19. How will the human genome project improve our quality of life?
20. Why pharmacogenomics? Why now?
21. Can pharmacogenomics make a difference in drug development?
22. Vetting
23. Shortcuts from gene sequence to function
24. A second human genome project?
25. Quantitative proteomics?
26. Gene expression analysis: What big pharma is looking for
27. Informatics: Coming to grips with complexity
28. Up-front payments in platform technology deals, revisited
29. Basic science and pharmaceutical innovation
30. Millennium mergers bring pipeline
31. Metabolic control analysis in biotechnology and medicine
32. Five stages of the human genome project
33. From genomics to epigenomics: A loftier view of life
34. Can biological phenomena be understood by humans?
35. Should you hire an epistemologist?
36. The coming Kuhnian revolution in biology